CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nacht, M.
Right arrow Articles by Jacks, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nacht, M.
Right arrow Articles by Jacks, T.

Cell Growth & Differentiation, Vol 9, Issue 2 131-138, Copyright © 1998 by American Association of Cancer Research


ARTICLES

V(D)J recombination is not required for the development of lymphoma in p53-deficient mice

M Nacht and T Jacks
Howard Hughes Medical Institute, Center for Cancer Research, Massachusetts Institute of Technology, Cambridge 02139, USA.

The most common tumor in p53-deficient mice is thymic lymphoma, and p53 is known to be required for the induction of apoptosis in thymocytes following DNA damage. To examine whether the development of thymic lymphoma in p53-/- mice was dependent on the process of V(D)J recombination, we generated p53-/- mice that were also mutant for the Rag1 or Rag2 genes. Both Rag1-/-; p53-/- and Rag2-/-; p53-/- mice developed thymic lymphoma at high frequency, and the tumors arose with short latency. Interestingly, the thymic tumors were composed of CD4+CD8+ cells, although there was no evidence for normal V(D)J recombination. These data suggest that normal V(D)J recombination is not required for the development of thymic lymphoma in the context of a p53 germ-line mutation.


This article has been cited by other articles:


Home page
BloodHome page
J. Hauer, C. Mullighan, E. Morillon, G. Wang, J. Bruneau, N. Brousse, M. Lelorc'h, S. Romana, A. Boudil, D. Tiedau, et al.
Loss of p19Arf in a Rag1-/- B-cell precursor population initiates acute B-lymphoblastic leukemia
Blood, July 21, 2011; 118(3): 544 - 553.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. A. Bertout, S. A. Patel, B. H. Fryer, A. C. Durham, K. L. Covello, K. P. Olive, M. H. Goldschmidt, and M. C. Simon
Heterozygosity for Hypoxia Inducible Factor 1{alpha} Decreases the Incidence of Thymic Lymphomas in a p53 Mutant Mouse Model
Cancer Res., April 1, 2009; 69(7): 3213 - 3220.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. Giblin, M. Chatterji, G. Westfield, T. Masud, B. Theisen, H.-L. Cheng, J. DeVido, F. W. Alt, D. O. Ferguson, D. G. Schatz, et al.
Leaky severe combined immunodeficiency and aberrant DNA rearrangements due to a hypomorphic RAG1 mutation
Blood, March 26, 2009; 113(13): 2965 - 2975.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Ozturk, J. H. Lee, S. Gaddameedhi, and A. Sancar
Loss of cryptochrome reduces cancer risk in p53 mutant mice
PNAS, February 24, 2009; 106(8): 2841 - 2846.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Xu, Q. Yu, R. Subrahmanyam, M. J. Difilippantonio, T. Ried, and J. M. Sen
{beta}-Catenin Expression Results in p53-Independent DNA Damage and Oncogene-Induced Senescence in Prelymphomagenic Thymocytes In Vivo
Mol. Cell. Biol., March 1, 2008; 28(5): 1713 - 1723.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Z. Guo, M. Dose, D. Kovalovsky, R. Chang, J. O'Neil, A. T. Look, H. von Boehmer, K. Khazaie, and F. Gounari
{beta}-Catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation
Blood, June 15, 2007; 109(12): 5463 - 5472.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. S. Chervinsky, D. H. Lam, M. P. Melman, K. W. Gross, and P. D. Aplan
scid Thymocytes with TCR{beta} Gene Rearrangements Are Targets for the Oncogenic Effect of SCL and LMO1 Transgenes
Cancer Res., September 1, 2001; 61(17): 6382 - 6387.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. J. Williams, I. Grandal, D. J. Vesprini, U. Wojtyra, J. S. Danska, and C. J. Guidos
Irradiation Promotes V(D)J Joining and RAG-Dependent Neoplastic Transformation in SCID T-Cell Precursors
Mol. Cell. Biol., January 15, 2001; 21(2): 400 - 413.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
R. Wen, D. Wang, C. McKay, K. D. Bunting, J.-C. Marine, E. F. Vanin, G. P. Zambetti, S. J. Korsmeyer, J. N. Ihle, and J. L. Cleveland
Jak3 Selectively Regulates Bax and Bcl-2 Expression To Promote T-Cell Development
Mol. Cell. Biol., January 15, 2001; 21(2): 678 - 689.
[Abstract] [Full Text] [PDF]


Home page
EMBO J.Home page
R. Pearson and K. Weston
c-Myb regulates the proliferation of immature thymocytes following {beta}-selection
EMBO J., November 15, 2000; 19(22): 6112 - 6120.
[Abstract] [Full Text] [PDF]


Home page
EMBO J.Home page
M. Baker, J. Gamble, R. Tooze, D. Higgins, F. T. Yang, P. C. M. O'Brien, N. Coleman, S. Pingel, M. Turner, and D. R. Alexander
Development of T-leukaemias in CD45 tyrosine phosphatase-deficient mutant lck mice
EMBO J., September 1, 2000; 19(17): 4644 - 4654.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. K. Petiniot, Z. Weaver, C. Barlow, R. Shen, M. Eckhaus, S. M. Steinberg, T. Ried, A. Wynshaw-Boris, and R. J. Hodes
Recombinase-activating gene (RAG) 2-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient mice
PNAS, June 6, 2000; 97(12): 6664 - 6669.
[Abstract] [Full Text] [PDF]


Home page
EMBO J.Home page
K. Newton, A. W. Harris, and A. Strasser
FADD/MORT1 regulates the pre-TCR checkpoint and can function as a tumour suppressor
EMBO J., March 1, 2000; 19(5): 931 - 941.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. J. Vanasse, P. Concannon, and D. M. Willerford
Regulated Genomic Instability and Neoplasia in the Lymphoid Lineage
Blood, December 15, 1999; 94(12): 3997 - 4010.
[Full Text] [PDF]


Home page
Genes Dev.Home page
M.-J. Liao and T. Van Dyke
Critical role for Atm in suppressing V(D)J recombination-driven thymic lymphoma
Genes & Dev., May 15, 1999; 13(10): 1246 - 1250.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
T. Kamijo, S. Bodner, E. van de Kamp, D. H. Randle, and C. J. Sherr
Tumor Spectrum in ARF-deficient Mice
Cancer Res., May 1, 1999; 59(9): 2217 - 2222.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. V. Iozzo, F. Chakrani, D. Perrotti, D. J. McQuillan, T. Skorski, B. Calabretta, and I. Eichstetter
Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis
PNAS, March 16, 1999; 96(6): 3092 - 3097.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M.-J. Liao, X.-X. Zhang, R. Hill, J. Gao, M. B. Qumsiyeh, W. Nichols, and T. Van Dyke
No Requirement for V(D)J Recombination in p53-Deficient Thymic Lymphoma
Mol. Cell. Biol., June 1, 1998; 18(6): 3495 - 3501.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1998 by the American Association of Cancer Research.